Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (81-90 of 177) with videos related to

Pageof 18
Sort By:
Expert Review of Neurotherapeutics|January 28, 2021
Istradefylline - a first generation adenosine A<sub>2A</sub> antagonist for the treatment of Parkinson's diseasePeter Jenner, Akihisa Mori, Stephen D Aradi, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 15, 2025
Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptorsBrittney Yegla, Jonathan Rubin, Mindy Grall, et al.
Brain Research|October 18, 2002
Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brainGrazyna Kunikowska, Imelda Gallagher, Vivette Glover, et al.
CNS Drugs|November 4, 2020
Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging TherapiesDaniele Urso, K Ray Chaudhuri, Mubasher A Qamar, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 18, 2012
Proteasome inhibition leads to early loss of synaptic proteins in neuronal cultureNatasha Bajic, Peter Jenner, Clive G Ballard, et al.
Pharmacology, Biochemistry, and Behavior|November 9, 2013
Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodentsKoji Yamada, Minoru Kobayashi, Akihisa Mori, et al.
Journal of Neurochemistry|November 9, 2002
Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?Dong-Hoon Hyun, Moon-Hee Lee, Barry Halliwell, et al.
Journal of Neurochemistry|July 2, 2004
Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseasesDong-Hoon Hyun, Douglas A Gray, Barry Halliwell, et al.
Annals of Neurology|July 25, 2006
Reproducible nigral cell loss after systemic proteasomal inhibitor administration to ratsBai-Yun Zeng, Salma Bukhatwa, Atsuko Hikima, et al.
Current Neuropharmacology|August 1, 2023
Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's DiseaseDaniel J van Wamelen, Valentina Leta, K Ray Chaudhuri, et al.
Pageof 18

Showing results (81-90 of 177) with videos related to

Sort By:
Pageof 18
Expert Review of Neurotherapeutics|January 28, 2021
Istradefylline - a first generation adenosine A<sub>2A</sub> antagonist for the treatment of Parkinson's diseasePeter Jenner, Akihisa Mori, Stephen D Aradi, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 15, 2025
Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptorsBrittney Yegla, Jonathan Rubin, Mindy Grall, et al.
Brain Research|October 18, 2002
Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brainGrazyna Kunikowska, Imelda Gallagher, Vivette Glover, et al.
CNS Drugs|November 4, 2020
Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging TherapiesDaniele Urso, K Ray Chaudhuri, Mubasher A Qamar, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|May 18, 2012
Proteasome inhibition leads to early loss of synaptic proteins in neuronal cultureNatasha Bajic, Peter Jenner, Clive G Ballard, et al.
Pharmacology, Biochemistry, and Behavior|November 9, 2013
Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodentsKoji Yamada, Minoru Kobayashi, Akihisa Mori, et al.
Journal of Neurochemistry|November 9, 2002
Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?Dong-Hoon Hyun, Moon-Hee Lee, Barry Halliwell, et al.
Journal of Neurochemistry|July 2, 2004
Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseasesDong-Hoon Hyun, Douglas A Gray, Barry Halliwell, et al.
Annals of Neurology|July 25, 2006
Reproducible nigral cell loss after systemic proteasomal inhibitor administration to ratsBai-Yun Zeng, Salma Bukhatwa, Atsuko Hikima, et al.
Current Neuropharmacology|August 1, 2023
Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's DiseaseDaniel J van Wamelen, Valentina Leta, K Ray Chaudhuri, et al.
Pageof 18